Table 1.
Patient characteristics and prevalence of transmitted drug resistance according to the WHO SDRM 2009 list.
| No TDR | Any TDR | Total | ||
|---|---|---|---|---|
| (n = 36, 84%) | (n = 7, 16%) | (n = 43) | p-value | |
| Male sex at birth (%) | 36 (100) | 7 (100) | 43 (100) | 1 |
| HIV risk exposure (%) | 1 | |||
| MSM | 34 (94.4) | 7 (100) | 41 (95.3) | |
| TGW | 1 (2.8) | 0 (0) | 1 (2.3) | |
| Heterosexual | 1 (2.8) | 0 (0) | 1 (2.3) | |
| Age, median (IQR) | 28.3 (25.8,33.2) | 26.4 (26,31.2) | 27.9 (25.8,33.4) | 0.657 |
| CD4, median (IQR) | 588 (412, 721) | 654 (453, 676) | 593 (418, 689) | 0.882 |
| VL log, median (IQR) | 4.9 (4.1, 5.5) | 4.1 (3.8, 5.6) | 4.8 (4.0, 5.6) | 0.645 |
| HIV subtype (%) | 0.456 | |||
| B | 23 (63.9) | 3 (42.9) | 26 (60.5) | |
| C | 7 (19.4) | 3 (42.9) | 10 (23.3) | |
| F | 2 (5.6) | 1 (14.3) | 3 (7) | |
| B/F | 1 (2.8) | 0 (0) | 1 (2.3) | |
| Other/unknown | 3 (8.3) | 0 (0) | 3 (7) | |
| Stage of HIV infection (%) | 0.655 | |||
| Acute | 10 (27.8) | 3 (42.9) | 13 (30.2) | |
| Recent | 26 (72.2) | 4 (57.1) | 30 (69.8) | |
| PReP uptake (%) | 0 (0) | 2 (28.6) | 2 (4.7) | 0.023 |
| PEP uptake (%) | 6 (16.7) | 1 (14.3) | 7 (16.3) | 1 |
TDR, transmitted drug resistance; MSM, men who have sex with men; TGW, transgender women; VL, HIV RNA viral load; PReP, pre-exposure prophylaxis; PEP, post-exposure prophylaxis.